Cavusoglu E, Frishman W H
Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA.
Prog Cardiovasc Dis. 1995 May-Jun;37(6):423-40. doi: 10.1016/s0033-0620(05)80022-2.
Sotalol is a water-soluble, nonselective, beta-adrenergic blocker that was recently approved in oral form in the United States for the treatment of ventricular arrhythmias that are judged to be life-threatening. As a beta-blocker, sotalol is unique in having additional class-III antiarrhythmic activity. It is still not resolved whether sotalol is more effective than other beta-blockers in managing arrhythmias, but there are suggestions that it might possess greater antiarrhythmic and life-protecting activities than other types of antiarrhythmic drugs. The drug is well tolerated, but, because of its electrophysiologic activity, there is a small risk of proarrhythmia, specifically the development of polymorphic ventricular tachycardia and torsade de pointes.
索他洛尔是一种水溶性、非选择性的β肾上腺素能阻滞剂，最近在美国被批准以口服形式用于治疗被判定为危及生命的室性心律失常。作为一种β阻滞剂，索他洛尔的独特之处在于具有额外的Ⅲ类抗心律失常活性。索他洛尔在治疗心律失常方面是否比其他β阻滞剂更有效仍未明确，但有迹象表明，它可能比其他类型的抗心律失常药物具有更强的抗心律失常和保护生命的活性。该药物耐受性良好，但由于其电生理活性，存在小的促心律失常风险，特别是多形性室性心动过速和尖端扭转型室速的发生。
